British-Swedish biotech company AstraZeneca intends to invest $4.5 billion in the construction of a new manufacturing facility in Virginia. This is reported in a press release from AstraZeneca.
Thus, AstraZeneca is increasing by $500 million the initial investment plan under the $50 billion program announced in July 2025, with the aim of expanding production capacity to produce a wider range of medicines, including drugs for cancer treatment.
The new facility, which is scheduled to be launched in 4-5 years, will produce medicinal substances for weight control and metabolism, including oral GLP-1, baxdrostat, oral PCSK9, and combined low-molecular-weight drugs.
The new facility will be located at Rivanna Futures in Albemarle County and will provide 3.6 thousand jobs, contributing to the economic growth of the state of Virginia in the field of technological innovations based on artificial intelligence, automation and data analysis to optimize production.
The investments will create the most important production facilities for the production of medicines in the United States and ensure guarantees of national security and sovereignty in the healthcare sector.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. She has a portfolio of products for the treatment of major diseases in areas such as oncology, cardiology and cardiac surgery.
